| Vasculitis and related conditions | Lifetime | 26 | CN 1 | 99.56 |
| Renal Diseases and Glomerulopathies | Lifetime | 55 | CN 2 | 99.53 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 119 | CN 1 | 98.66 |
| Complement system in diseases | Lifetime | 105 | CN 1 | 98.59 |
| Systemic Lupus Erythematosus Research | Lifetime | 293 | CN 7 | 99.01 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 141 | CN 1 | 98.48 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 150 | CN 1 | 97.96 |
| Chronic Kidney Disease and Diabetes | Lifetime | 242 | CN 8 | 98.55 |
| Cell Adhesion Molecules Research | Lifetime | 619 | CN 11 | 98.11 |
| Autoimmune Bullous Skin Diseases | Lifetime | 353 | CN 4 | 97.45 |
| Dialysis and Renal Disease Management | Lifetime | 606 | CN 17 | 97.36 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 231 | CN 2 | 96.59 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 534 | CN 19 | 96.69 |
| Inflammasome and immune disorders | Lifetime | 462 | CN 39 | 95.94 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 127 | CN 3 | 96.22 |
| Urticaria and Related Conditions | Lifetime | 935 | CN 9 | 93.45 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 672 | CN 5 | 89.09 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 513 | CN 90 | 75.72 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 24 | CN 5 | 99.12 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 75 | CN 8 | 97.89 |
| Complement system in diseases | 2021-2025 | 37 | CN 2 | 97.43 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 223 | CN 20 | 96.71 |
| Vasculitis and related conditions | 2021-2025 | 93 | CN 4 | 96.63 |
| Dialysis and Renal Disease Management | 2021-2025 | 218 | CN 13 | 95.59 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 168 | CN 2 | 93.85 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 602 | CN 96 | 91.89 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 217 | CN 9 | 92.86 |
| Cell Adhesion Molecules Research | 2021-2025 | 232 | CN 27 | 85.51 |
| Kidney Stones and Urolithiasis Treatments | 2021-2025 | 325 | CN 57 | 89.44 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 383 | CN 13 | 85.99 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 549 | CN 108 | 82.50 |
| Platelet Disorders and Treatments | 2021-2025 | 710 | CN 75 | 83.02 |
| Biomedical Research and Pathophysiology | 2021-2025 | 104 | CN 8 | 80.92 |
| Advanced Glycation End Products research | 2021-2025 | 472 | CN 194 | 71.81 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 534 | CN 28 | 64.24 |
| Ureteral procedures and complications | 2021-2025 | 913 | CN 111 | 64.20 |
| Potassium and Related Disorders | 2021-2025 | 663 | CN 28 | 62.51 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 728 | CN 31 | 60.35 |
